FibroGen (NASDAQ:FGEN) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research report sent to investors on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

FibroGen Price Performance

NASDAQ FGEN opened at $0.32 on Monday. FibroGen has a fifty-two week low of $0.30 and a fifty-two week high of $2.93. The business has a 50 day moving average price of $0.38 and a two-hundred day moving average price of $0.81. The stock has a market cap of $31.83 million, a PE ratio of -0.13 and a beta of 0.70.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.09. The firm had revenue of $50.64 million during the quarter, compared to analysts’ expectations of $33.00 million. During the same quarter last year, the company posted ($0.65) earnings per share. Sell-side analysts anticipate that FibroGen will post -0.91 EPS for the current fiscal year.

Institutional Trading of FibroGen

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC increased its stake in shares of FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock worth $2,997,000 after buying an additional 860,854 shares during the last quarter. AQR Capital Management LLC grew its holdings in FibroGen by 139.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after acquiring an additional 769,586 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of FibroGen in the 3rd quarter worth about $307,000. XTX Topco Ltd acquired a new stake in shares of FibroGen in the 2nd quarter valued at about $424,000. Finally, Cubist Systematic Strategies LLC lifted its position in shares of FibroGen by 3,906.9% during the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after purchasing an additional 280,161 shares during the last quarter. 72.71% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.